Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Natus Medical Inc    BABY

NATUS MEDICAL INC (BABY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Natus Medical Inc : Natus Medical to Hold 2012 First Quarter Financial Results Conference Call on April 26

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 01:05pm CEST

Natus Medical Incorporated (NASDAQ:BABY) today announced that the Company intends to release its 2012 first quarter financial results before the market opens on Thursday, April 26, 2012. Natus management will host an investment-community conference call the same day beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) to discuss those results and to answer questions.

Individuals interested in listening to the conference call may do so by dialing 888-268-4176 for domestic callers, or 1-617-597-5493 for international callers, and entering reservation code 32875965. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 888-286-8010 for domestic callers, or 1-617-801-6888 for international callers, and entering reservation code 56980616.

The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company's Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

Additional information about Natus Medical can be found at www.natus.com.

Natus Medical Incorporated
Steven J. Murphy, 650-802-0400
[email protected]
Vice President and Chief Financial Officer


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NATUS MEDICAL INC
04/16NATUS MEDICAL : Otometrics Announces Launch of Bio-logic Solutions at AAA 2018
AQ
04/11NATUS MEDICAL, INC 65IIA MEDICAL EQU : 4/15/2018-4/14/2023
AQ
04/11Natus Medical to Hold 2018 First Quarter Financial Results Conference Call on..
GL
04/1065-- NATUS MEDICAL, INC 65IIA MEDICA : 4/15/2018-4/14/2023
AQ
03/27NATUS MEDICAL : Xltek EEG Monitoring system
AQ
03/08NATUS MEDICAL : 65-- 674-18-2-3485-0007 - EEG/Sleep System
AQ
03/05Natus to Present at 30th Annual Roth Conference
GL
03/01NATUS MEDICAL : Management's Discussion and Analysis of Financial Condition and ..
AQ
02/22NATUS MEDICAL INC : Other Events (form 8-K)
AQ
02/22Natus Announces $30 Million Share Repurchase Program
GL
More news
News from SeekingAlpha
03/02Key events next week - healthcare 
02/22Natus to buy back $30M of stock; shares up 4% 
02/07Natus Medical's (BABY) CEO Jim Hawkins on Q4 2017 Results - Earnings Call Tra.. 
02/07Natus Medical Q4 revenues up 22%; non-GAAP EPS down 18%; updates guidance 
02/07Natus Medical misses by $0.12, misses on revenue 
Financials ($)
Sales 2018 537 M
EBIT 2018 71,5 M
Net income 2018 30,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 41,34
P/E ratio 2019 33,63
Capi. / Sales 2018 2,23x
Capi. / Sales 2019 2,15x
Capitalization 1 197 M
Chart NATUS MEDICAL INC
Duration : Period :
Natus Medical Inc Technical Analysis Chart | BABY | US6390501038 | 4-Traders
Technical analysis trends NATUS MEDICAL INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 44,0 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
James B. Hawkins President, Chief Executive Officer & Director
Robert A. Gunst Chairman
Jonathan A. Kennedy Chief Financial Officer & Executive Vice President
D. Christopher Chung VP-Medical Affairs, Quality & Regulatory
Doris E. Engibous Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NATUS MEDICAL INC-5.50%1 197
THERMO FISHER SCIENTIFIC13.70%86 857
DANAHER CORPORATION9.18%70 780
INTUITIVE SURGICAL25.03%51 587
BOSTON SCIENTIFIC CORPORATION16.54%39 785
ROYAL PHILIPS4.41%38 068